$DGX News

Quest Diagnostics's Q2 2026 Earnings: What to Expect

Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry

Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs

DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

Quest Diagnostics Receives New York's Department of Health's Clinical Laboratory Evaluation Program Approval For Its Haystack Minimal Residual Disease Liquid Biopsy Test To Trace Residual Or Recurring Disease In Solid Tumor Cancers Patients

Is Quest Diagnostics Stock Underperforming the S&P 500?

UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics

Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026

Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report

Quest Diagnostics Inc (NYSE:DGX): A Top Dividend Stock with Sustainable Income and Growth Potential

Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, LifeStance Health and Aveanna Healthcare

How The Quest Diagnostics (DGX) Investment Story Is Evolving Without New Analyst Price Target Changes

Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know

3 Reasons to Sell DGX and 1 Stock to Buy Instead

Are Medical Stocks Lagging Quest Diagnostics (DGX) This Year?

Quest Diagnostics Stock: Analyst Estimates & Ratings

Why Is Quest Diagnostics (DGX) Down 5% Since Last Earnings Report?

Reasons to Add Align Technology Stock to Your Portfolio Now

Quest Diagnostics Declares Quarterly Cash Dividend